Biochemical and pathological characterization of Lrrk2

被引:181
作者
Giasson, BI
Covy, JP
Bonini, NM
Hurtig, HI
Farrer, MJ
Trojanowski, JQ
Van Deerlin, VM
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA
[3] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[6] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
D O I
10.1002/ana.20791
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Mutations in leucine-rich repeat kinase 2 (LRRK2) recently have been identified as the most common genetic cause of late-onset sporadic and familial Parkinson's disease (PD). The studies herein explore the biological and pathological properties of Lrrk2. Methods: Genetic analysis was per-formed to identify autopsied patients with the most common Lrrk2 mutation (G2019S). Using an antibody specific to Lrrk2, the biochemical and immunocytochemical distribution of Lrrk2 was assessed. Results. Three patients with the G2019S Lrrk2 mutation were identified. Two patients demonstrated classic PD with Lewy bodies, although concurrent pathological changes consistent with Alzheimer's disease were also present in one of these individuals. The third patient was characterized by parkinsonism without Lewy bodies but demonstrated dystrophic neurites in the substantia nigra intensely stained for Lrrk2. Lrrk2 accumulations were unique to this patient and Lrrk2 was not detected in other types of pathological inclusions. Biochemical analysis showed that Lrrk2 is predominantly a soluble approximately 250kDa cytoplasmic protein expressed throughout the brain but also in many other organs. Interpretation The reasons for the selective predisposition of patients with mutations in LRRK2 to develop parkinsonism remains unclear, but Lrrk2 mutations may prime select neuronal populations to cellular insults that can lead to aberrant protein aggregation.
引用
收藏
页码:315 / 322
页数:8
相关论文
共 30 条
[1]   Clinical features of LRRK2-associated Parkinson's disease in Central Norway [J].
Aasly, JO ;
Toft, M ;
Fernandez-Mata, I ;
Kachergus, J ;
Hulihan, M ;
White, LR ;
Farrer, M .
ANNALS OF NEUROLOGY, 2005, 57 (05) :762-765
[2]  
Baba M, 1998, AM J PATHOL, V152, P879
[3]   Staging of brain pathology related to sporadic Parkinson's disease [J].
Braak, H ;
Del Tredici, K ;
Rüb, U ;
de Vos, RAI ;
Steur, ENHJ ;
Braak, E .
NEUROBIOLOGY OF AGING, 2003, 24 (02) :197-211
[4]  
Cronford M.E., 1995, BRAIN COGNITION, V28, P321
[5]   Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation [J].
Deng, H ;
Le, WD ;
Guo, Y ;
Hunter, CB ;
Xie, WJ ;
Jankovic, J .
ANNALS OF NEUROLOGY, 2005, 57 (06) :933-934
[6]  
Di Fonzo A, 2005, LANCET, V365, P412
[7]   Immunohistochemical and biochemical studies demonstrate a distinct profile of α-synuclein permutations in multiple system atrophy [J].
Duda, JE ;
Giasson, BI ;
Gur, TL ;
Montine, TJ ;
Robertson, D ;
Biaggioni, I ;
Hurtig, HI ;
Stern, MB ;
Gollomp, SM ;
Grossman, M ;
Lee, VMY ;
Trojanowski, JQ .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (09) :830-841
[8]   Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases [J].
Duda, JE ;
Giasson, BI ;
Mabon, ME ;
Lee, VMY ;
Trojanowski, JQ .
ANNALS OF NEUROLOGY, 2002, 52 (02) :205-210
[9]   LRRK2 mutations in Parkinson disease [J].
Farrer, M ;
Stone, J ;
Mata, IF ;
Lincoln, S ;
Kachergus, J ;
Hulihan, M ;
Strain, KJ ;
Maraganore, DM .
NEUROLOGY, 2005, 65 (05) :738-740
[10]   Nosology of Parkinson's disease: Looking for the way out of a quackmire [J].
Forman, MS ;
Lee, VMY ;
Trojanowski, JQ .
NEURON, 2005, 47 (04) :479-482